Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 million (around $16 million) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback